» Articles » PMID: 30922652

Role of Aneuploidy Screening in Preimplantation Genetic Testing for Monogenic Diseases in Young Women

Overview
Journal Fertil Steril
Date 2019 Mar 30
PMID 30922652
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To investigate whether aneuploidy screening in preimplantation genetic testing (PGT) for monogenic diseases improves the ongoing pregnancy/live birth rate of single frozen/thawed embryo transfer (FET) cycles in young women.

Design: Retrospective cohort study.

Setting: Single university-based fertility center.

Patient(s): From January 2016 to December 2017, 569 FET cycles were selected for analysis. The aneuploidy screening (AS) group included 131 FET cycles from 105 oocyte retrieval cycles in 98 patients who underwent PGT for monogenic diseases with aneuploidy screening, and the non-AS group included 438 FET cycles from 280 oocyte retrieval cycles in 266 patients who underwent PGT for monogenic diseases without aneuploidy screening.

Intervention(s): The patient population was all under the age of 35 years and underwent PGT for monogenic diseases with and without AS.

Main Outcome Measure(s): Ongoing pregnancy/live birth rate, live birth rate, implantation rate, and miscarriage rate.

Result(s): Aneuploidy screening significantly improved the ongoing pregnancy/live birth rate (61.22% vs. 43.98%), implantation rate (64.29% vs. 50.38%), and live birth rate (53.06% vs. 36.09%) of young women carrying monogenic diseases in the first FET cycles. When adjusted for the parity, number of previous miscarriages, and percentage of infertility, the likelihood of implantation was 1.874 times higher (95% confidence interval 1.126-3.119), and an ongoing pregnancy/live birth was 2.139 times more likely (95% confidence interval 1.295-3.534). In addition, the miscarriage rate was significantly decreased (3.17% vs. 11.94%). In the cumulative pregnancy outcomes, the cumulative ongoing pregnancy/live birth rate both per transfer and per patient were significantly higher in the AS group (62.24% vs. 50.38% and 79.59% vs. 68.80%), but no difference existed after adjusting for the parity, number of previous miscarriage, and percentage of infertility. Nevertheless, aneuploidy screening reduced the time interval from the first ET to the achievement a pregnancy.

Conclusion(s): Aneuploidy screening in PGT significantly improved the ongoing pregnancy/live birth rate of young women carrying monogenic diseases in the first FET cycles.

Citing Articles

Aligning genotyping and copy number data in single trophectoderm biopsies for aneuploidy prediction: uncovering incomplete concordance.

De Witte L, Baetens M, Tilleman K, Vanden Meerschaut F, Janssens S, Van Tongerloo A Hum Reprod Open. 2024; 2024(4):hoae056.

PMID: 39391861 PMC: 11461285. DOI: 10.1093/hropen/hoae056.


Appropriate whole genome amplification and pathogenic loci detection can improve the accuracy of preimplantation genetic diagnosis for deletional α-thalassemia.

Lan Y, Zhou H, He S, Shu J, Liang L, Wei H Front Endocrinol (Lausanne). 2024; 14:1176063.

PMID: 38523870 PMC: 10957767. DOI: 10.3389/fendo.2023.1176063.


A comprehensive preimplantation genetic testing approach for SEA-type α-thalassemia by fluorescent gap-polymerase chain reaction combined with haplotype analysis.

Wang J, Ma Y, Guo J, Li R, Zhou C, Xu Y Front Genet. 2023; 14:1248358.

PMID: 38075678 PMC: 10702134. DOI: 10.3389/fgene.2023.1248358.


Do chromosomal inversion carriers really need preimplantation genetic testing?.

Tong J, Jiang J, Niu Y, Zhang T J Assist Reprod Genet. 2022; 39(11):2573-2579.

PMID: 36367623 PMC: 9723079. DOI: 10.1007/s10815-022-02654-2.


A Mini-Review Regarding the Clinical Outcomes of In Vitro Fertilization (IVF) Following Pre-Implantation Genetic Testing (PGT)-Next Generation Sequencing (NGS) Approach.

Doroftei B, Ilie O, Anton N, Armeanu T, Ilea C Diagnostics (Basel). 2022; 12(8).

PMID: 36010262 PMC: 9406843. DOI: 10.3390/diagnostics12081911.